WO2017073897A1 - Pharmaceutical composition comprising metformin and lobeglitazone - Google Patents

Pharmaceutical composition comprising metformin and lobeglitazone Download PDF

Info

Publication number
WO2017073897A1
WO2017073897A1 PCT/KR2016/009393 KR2016009393W WO2017073897A1 WO 2017073897 A1 WO2017073897 A1 WO 2017073897A1 KR 2016009393 W KR2016009393 W KR 2016009393W WO 2017073897 A1 WO2017073897 A1 WO 2017073897A1
Authority
WO
WIPO (PCT)
Prior art keywords
metformin
lobeglitazone
pharmaceutically acceptable
acceptable salt
pharmaceutical formulation
Prior art date
Application number
PCT/KR2016/009393
Other languages
English (en)
French (fr)
Inventor
Eun Ji Shin
Min Kwan Cho
Teak Hwan SHIN
Shin Jung Park
Jong Rae Lim
Original Assignee
Chong Kun Dang Pharmaceutical Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp. filed Critical Chong Kun Dang Pharmaceutical Corp.
Publication of WO2017073897A1 publication Critical patent/WO2017073897A1/en
Priority to PH12018500817A priority Critical patent/PH12018500817A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a pharmaceutical composition containing metformin and lobeglitazone as active ingredients.
  • Type 2 diabetes is a disease associated with insulin secretion disorder due to insulin resistance (i.e. a condition in which the reactivity of cells or tissue to insulin at a given insulin concentration is decreased below normal) and ⁇ -cell dysfunction of the pancreas, 85 % or more of diabetes patients correspond to adult-onset Type 2 diabetes, and the number of patients with Type 2 diabetes is continuously increasing owing to the decreasing physical activity habits of modern people and with the increase in obesity.
  • Type 2 diabetes shows hyperinsulinemia due to glucose intolerance and insulin resistance in the early stages and then progresses to hyperglycemia and hypoinsulinemia.
  • the selection of a drug that exhibits effectiveness adapted for a given stage of disease is regarded as very important in the treatment of diabetes.
  • oral hypoglycemic agents may be classified into, depending on the action mechanism, 1) insulin secretagogues (sulfonylurea, non-sulfonylurea), 2) biguanide-based drugs, 3) alpha-glycosidase inhibitors, 4) glitazone-based drugs, 5) DPP-IV inhibitors, and 6) SGLT-2 inhibitors.
  • Metformin which is one of the biguanide-based drugs, is an oral drug useful as a primary medicament in the treatment of Type 2 diabetes, and is represented by Chemical Formula 1 below.
  • Metformin functions to increase insulin sensitivity in the peripheral tissue of the host, and is associated with the inhibition of glucose uptake from the intestine, the suppression of hepatic gluconeogenesis, and the inhibition of fatty acid oxidation to thereby result in glycemic control.
  • the glycemic control mechanism of metformin is independent of insulin secretion, induces a reduction in the body weight of diabetes patients, and exhibits effects of lowering blood triglyceride and low-density lipoproteins and increasing high-density lipoproteins.
  • metformin may be utilized as a primary medicament for the treatment of Type 2 diabetes patients that show insulin resistance.
  • metformin which occur in 20 to 30% of patients to which metformin is administered, are known to include loss of appetite, abdominal distension, nausea, diarrhea and the like. Most such side effects are transient and thus disappear 2 to 3 weeks after the use thereof, but the use thereof has to be stopped in cases where diarrhea or severe abdominal distension fails to disappear. In rare cases, it can cause skin rashes and hives.
  • These side effects may be ameliorated by the use of a sustained-release formulation that is able to decrease the minimum and/or sustainable dose or to lower the frequency of prescription.
  • a glitazone-based drug is a PPAR ⁇ agonist (Peroxisome Proliferator Activated Receptor gamma agonist), and stimulates PPAR ⁇ , which is expressed in adipocytes to promote adipogenesis and glucose uptake, thereby increasing insulin sensitivity in vivo .
  • the glitazone-based drug has no mechanism for promoting insulin secretion and is thus favorable for protecting ⁇ -cells of the pancreas, and may improve insulin resistance and is thus particularly effective in the treatment of diabetes patients showing insulin resistance.
  • this drug is known to maintain the glucose level for a long period of time, slow the progress of Type 2 diabetes, and exhibit higher therapeutic effects on early diabetes.
  • Such a glitazone-based drug is currently exemplified by drugs having a thiazolidinedione (TZD) structure.
  • ZD thiazolidinedione
  • the glitazone-based drug when used alone, its antidiabetic activity is not high and limited therapeutic effects result. It is known to cause side effects such as edema or weight gain depending on the person.
  • lobeglitazone is a drug developed by the present applicant, and is represented by Chemical Formula 2 below.
  • Lobeglitazone has stable molecular dynamic energy, is structurally adapted for the active site pocket of PPAR ⁇ to thus exhibit high drug activity, and is responsible for overcoming the difficulty in lowering the lipid concentration in blood, which is noted as the defect of conventional glitazone-based drugs.
  • Diabetes is a complex group of diseases with a variety of causes and individual diabetes therapeutic agents have distinct advantages and disadvantages, and thus combination therapy using two or more antidiabetic agents having different action mechanisms in order to exhibit simultaneous actions on multiple targets is widely clinically prescribed.
  • Such combination therapy is remarkably improved in glycemic control compared to single therapy, and may decrease the likelihood of causing various side effects due to the administration of a high-dose single active ingredient.
  • the co-administration of two or more drugs suffers from poor medication compliance of patients. Accordingly, there is a continuous need to develop a combination formulation in which two or more active ingredients may be administered as a single medicament.
  • a glitazone-based drug is known to be effective upon co-administration with a drug having a different action mechanism.
  • the glitazone-based drug may be co-administered with metformin.
  • European Patent Publication No. 0749751 discloses a combination formulation of pioglitazone and metformin
  • International Patent Publication No. WO 98/57634 discloses a combination formulation of rosiglitazone and metformin.
  • the present invention has been made keeping in mind the above problems encountered in the related art, and the present invention is intended to provide a pharmaceutical composition containing metformin and lobeglitazone, which may exhibit superior therapeutic activity for Type 2 diabetes and related diseases and is able to reduce the side effects of a single active ingredient.
  • the present invention is intended to provide a pharmaceutical formulation, which enables the sustained release of metformin and the immediate release of lobeglitazone, and may exhibit equivalent pharmacokinetic (PK) data and superior physical stability and chemical stability compared to co-administration of single formulations.
  • PK pharmacokinetic
  • the present invention provides a pharmaceutical composition containing metformin and lobeglitazone and a pharmaceutical formulation including the same. Below is a detailed description thereof.
  • composition comprising metformin and lobeglitazone
  • the present invention provides a pharmaceutical composition, comprising: (A1) metformin or a pharmaceutically acceptable salt thereof and (A2) lobeglitazone or a pharmaceutically acceptable salt thereof, as active ingredients.
  • both (A1) metformin or a pharmaceutically acceptable salt thereof and (A2) lobeglitazone or a pharmaceutically acceptable salt thereof, used as active ingredients are drugs that do not promote insulin secretion and that improve insulin resistance.
  • the pharmaceutical composition of the present invention is able to exhibit the glycemic control effect while maintaining the functions of ⁇ -cells of the pancreas.
  • the pharmaceutically acceptable salt of metformin is preferably a hydrochloride, and the pharmaceutically acceptable salt of lobeglitazone is preferably a sulfate.
  • (A1) metformin or the pharmaceutically acceptable salt thereof may be contained in an amount of 250 to 2000 mg, and preferably 500 to 1000 mg.
  • (A2) lobeglitazone or the pharmaceutically acceptable salt thereof may be contained in an amount of 0.1 to 2.0 mg, and preferably 0.2 to 1.0 mg.
  • the pharmaceutical composition according to the present invention enables the co-administration of, as agents for improving insulin resistance having different action mechanisms, (A1) metformin or a pharmaceutically acceptable salt thereof and (A2) lobeglitazone or a pharmaceutically acceptable salt thereof, and may exhibit a synergistic effect on glycemic control compared to administration of a single active ingredient. Furthermore, the pharmaceutical composition of the present invention manifests a synergistic effect by the co-administration, and thus individual active ingredients may be contained in lower amounts, and the potential to generate side effects upon high-dosage administration may be excluded.
  • the pharmaceutical composition according to the present invention may be effective in the prevention or treatment of diabetes, especially Type 2 diabetes.
  • composition comprising metformin and lobeglitazone
  • the present invention provides a pharmaceutical formulation containing (A1) metformin or a pharmaceutically acceptable salt thereof and (A2) lobeglitazone or a pharmaceutically acceptable salt thereof.
  • metformin or the pharmaceutically acceptable salt thereof which is well dissolved in water
  • excessive glucose lowering may be caused due to the sudden release, and gastrointestinal disorders may occur.
  • metformin or the pharmaceutically acceptable salt thereof is administered in a large amount, side effects of metformin and resistance thereto may become increased on account of drastic changes in blood concentration due to rapid release.
  • serum half-life of metformin is as short as 2 to 6 hr, the sustained release of metformin or the pharmaceutically acceptable salt thereof is required.
  • the pharmaceutical formulation according to the present invention may be configured to include (L1) a core layer containing metformin or a pharmaceutically acceptable salt thereof as an active ingredient and (L2) an outer layer containing lobeglitazone or a pharmaceutically acceptable salt thereof as an active ingredient.
  • metformin or the pharmaceutically acceptable salt thereof, which is the active ingredient of the core layer may be contained in an amount of 250 to 2000 mg, and preferably 500 to 1000 mg, and is also preferably present in an amount of 60 to 80 wt% based on the total weight of the core layer.
  • the core layer (L1) may include a water-soluble polymer, so as to enable the sustained release of metformin or the pharmaceutically acceptable salt thereof.
  • the water-soluble polymer may be at least one selected from the group consisting of hydroxypropyl methylcellulose (e.g. hypromellose, etc.), hydroxypropylcellulose, ethyl cellulose, methyl cellulose, polyvinyl pyrrolidone, polymethacrylate, and mixtures thereof. Particularly useful is hydroxypropyl methylcellulose.
  • the water-soluble polymer is preferably present in an amount of 15 to 25 wt% based on the total weight of the core layer.
  • lobeglitazone or the pharmaceutically acceptable salt thereof, which is the active ingredient of the outer layer may be contained in an amount of 0.1 to 2.0 mg, and preferably 0.2 to 1.0 mg, and is also preferably present in an amount of 0.1 to 2.0 wt% based on the total weight of the outer layer.
  • lobeglitazone or the pharmaceutically acceptable salt thereof is used in a very small amount, and the outer layer (L2) containing it as the active ingredient may be a coating layer.
  • the outer layer (L2) may include a binder having a viscosity of 6 mPa.s or less so as to increase the coating yield of the outer layer.
  • the binder may be at least one selected from the group consisting of hydroxypropyl methylcellulose, polyvinyl pyrrolidone, lactose, and mixtures thereof. Preferably useful is hydroxypropyl methylcellulose or polyvinyl pyrrolidone, but the present invention is not limited thereto.
  • the outer layer may include a plasticizer.
  • the plasticizer is preferably triethyl citrate.
  • the amount of the plasticizer is about 2.5 to 15 wt%, and preferably about 5 to 10 wt%, based on the total weight of the outer layer.
  • the pharmaceutical formulation may further include (L3) an inert intermediate layer between the core layer and the outer layer.
  • the intermediate layer may include a binder and/or a plasticizer, and the binder and the plasticizer used for the outer layer may be used unchanged, but the present invention is not limited thereto.
  • the pharmaceutical formulation according to the present invention enables the sustained release of metformin or the pharmaceutically acceptable salt thereof and the immediate release of lobeglitazone or the pharmaceutically acceptable salt thereof, may maintain a constant blood concentration for 24 hr via administration once a day, and may manifest an excellent synergistic effect in the treatment of diabetes. Also, the pharmaceutical formulation of the present invention may show equivalent PK data compared to co-administration of a single formulation containing metformin or a pharmaceutically acceptable salt thereof and a single formulation containing lobeglitazone or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical formulation according to the present invention may further include a pharmaceutically acceptable additive.
  • the additive may be contained in an amount of 5 to 90 wt% based on the total weight of the pharmaceutical formulation.
  • examples of the additive may include a binder, a disintegrator, a lubricant, etc., and any additive may be used so long as it is typically useful in each dosage form and is pharmaceutically acceptable.
  • the binder may be selected from the group consisting of polyvinyl pyrrolidone (povidone), a copolymer of vinyl pyrrolidone and other vinyl derivatives (copovidone), microcrystalline cellulose, hydroxypropyl methylcellulose, methyl cellulose, hydroxypropylcellulose, and pregelatinized starch. Preferably useful is hydroxypropyl methylcellulose or povidone.
  • the disintegrator may be selected from the group consisting of croscarmellose sodium (crosslinked carboxymethylcellulose sodium), sodium starch glycolate, crospovidone (crosslinked polyvinyl pyrrolidone), corn starch, pregelatinized starch, low substituted hydroxypropylcellulose, and microcrystalline cellulose.
  • croscarmellose sodium crosslinked carboxymethylcellulose sodium
  • sodium starch glycolate sodium starch glycolate
  • crospovidone crosslinked polyvinyl pyrrolidone
  • corn starch pregelatinized starch
  • pregelatinized starch low substituted hydroxypropylcellulose
  • microcrystalline cellulose Preferably useful is sodium glycolate or crospovidone.
  • the lubricant may be colloidal silicon dioxide, sodium stearyl fumarate or magnesium stearate. Preferably useful is magnesium stearate.
  • the pharmaceutical formulation according to the present invention may be manufactured by techniques widely known to those skilled in the art. Specifically, in order to provide a core layer (L1) containing metformin or a pharmaceutically acceptable salt thereof as an active ingredient, a sustained-release-type metformin composition is produced using a wet granulation process and tableted using an automatic tableting machine, thereby forming a tablet layer. Lobeglitazone or a pharmaceutically acceptable salt thereof is dissolved in an appropriate solvent, stirred together with a binder and a plasticizer, sprayed onto the tablet, and dried. This coating may be performed using a typical process, and aqueous coating using a pan coating process for tablet coating is preferably carried out.
  • the coating process is preferably performed while the aqueous suspension of the binder is sprayed.
  • the coating process is conducted using the aqueous suspension without the use of an organic solvent, and thus problems such as environmental pollution due to the use of organic solvents may not occur.
  • a pharmaceutical composition can exhibit synergistic effects on the therapeutic activity of diabetes and can reduce the side effects of a single active ingredient.
  • a pharmaceutical formulation enables the sustained release of metformin and the immediate release of lobeglitazone, and can manifest equivalent PK data compared to co-administration of single formulations, and high physical stability and chemical stability thereof can result.
  • FIG. 1 is a graph showing the results of dissolution testing of Examples 1, 5, 6, and 9 using a paddle process (50 rpm and 37°C) in a pH 1.2 dissolution medium;
  • FIG. 2 is a graph showing the blood concentration of metformin upon administration of a combination composition according to the present invention and upon co-administration of single formulations of Comparative Examples 7 and 8;
  • FIG. 3 is a graph showing the blood concentration of lobeglitazone upon administration of the combination composition according to the present invention and upon co-administration of the single formulations of Comparative Examples 7 and 8.
  • Example 1 Preparation of pharmaceutical formulation according to the present invention
  • Step 1 Preparation of a core layer containing metformin or pharmaceutically acceptable salt thereof
  • a granular mixture of metformin or a pharmaceutically acceptable salt thereof was prepared through the following method using components in the amounts shown in Table 1 below.
  • Metformin hydrochloride, hypromellose 2208, and croscarmellose sodium were mixed, and kneaded with purified water, thus forming granules, which were then dried and sieved.
  • the sieved granules of 1) above were placed in a mixer, and mixed with colloidal silicon dioxide and magnesium stearate, which were sieved, thus obtaining a final mixture.
  • the final mixture of 2) above was tableted using an automatic tableting machine (XP1, Korsch, Germany), thus obtaining a tablet (a core layer) having a total weight of 1404 mg.
  • Step 2 Coating with an intermediate layer
  • An intermediate layer was formed on the surface of the tablet (core layer) obtained in Step 1 through the following method using components in the amounts shown in Table 2 below.
  • the tablet (core layer) obtained in Step 1 was placed in a coating machine (HC-LABO, FREUND, Germany), onto which the spray solution of 1) above was then sprayed and dried, thus obtaining a coating having a total weight of 1432 mg.
  • Step 3 Coating with an outer layer containing lobeglitazone or pharmaceutically acceptable salt thereof
  • An outer layer containing lobeglitazone or a pharmaceutically acceptable salt thereof was formed through the following method using components in the amounts shown in Table 3 below.
  • the tablet obtained in Step 2 was placed in a coating machine (HC-LABO, FREUND, Germany), onto which the spray solution of 1) above was then sprayed and dried, thus obtaining a tablet having a total weight of 1532 mg.
  • Comparative Examples 7 and 8 Single composition containing metformin or lobeglitazone as an active ingredient
  • composition containing metformin hydrochloride 1000 mg Glucophage XR tablets (extended release), made by and purchased from Merck, were used (Comparative Example 7). Also, as a composition containing lobeglitazone sulfate, 0.5 mg Duvie tablets, made by and purchased from the present applicant (Chong Kun Dang Pharmaceutical Corp.), were used (Comparative Example 8).
  • Test Example 1 Measurement of amount of combination composition according to the present invention
  • the amounts of metformin and lobeglitazone of Example 1 were measured.
  • the measurement method was as follows.
  • UV spectrophotometer (measurement wavelength: 255 nm)
  • UV spectrophotometer (measurement wavelength: 250 nm)
  • the amounts of metformin and lobeglitazone of Example 1 were measured to be about 98 % and about 99 %, respectively, as shown in Table 8 below. These values fell in the amount range of 90 to 110 %, corresponding to the amount standard of the combination composition, from which tableting and coating processes can be confirmed to be appropriately performed.
  • Test Example 2 Evaluation of pharmacological effects of combination composition of the present invention
  • the primary purpose of this clinical test is to prove that when comparing changes after 24 weeks from baseline for HbA1c in each administered group, the group administered with the combination composition containing lobeglitazone and metformin shows non-inferiority in terms of an HbA1c reduction effect, compared to the group administered with the combination composition containing pioglitazone and metformin.
  • the lower limit of the confidence interval was measured to be -0.16, which is greater than -0.4, corresponding to an allowable non-inferiority tolerance, from which non-inferiority could be confirmed.
  • Secondary effectiveness evaluation was performed using glycemic parameters and lipid parameters. Based on the comprehensive results of tests on glycemic parameters, administration of the lobeglitazone composition was found to realize the effective glycemic control and improve the insulin functions, and such results are similar to the change pattern of the group administered with the pioglitazone composition.
  • total cholesterol and LDL-C were significantly increased in both the lobeglitazone composition-administered group and the pioglitazone composition-administered group.
  • Triglyceride was significantly decreased in both of the administered groups, and HDL-C, small dense LDL-C, and FFA were statistically significantly improved.
  • Test Example 3 Evaluation of effect depending on viscosity of binder contained in the outer layer
  • the viscosity of a coating solution varies depending on the viscosity of the binder used upon coating with the outer layer, which may have an influence on the coating yield and appearance of a coating. In order to evaluate the effects depending on the viscosity of the binder, testing was performed at different viscosities of the binder.
  • Example 1 The formulations of Examples 1 to 4 and Comparative Example 1 were obtained under the condition that the viscosity of the binder contained in the coating solution of the outer layer was changed from 3 mPa.s to 15 mPa.s. After the coating process, the coating yield and appearance were measured. The appearance was observed using a digital microscope (KH-7700, HIROX, Japan).
  • Examples 1 to 4 were uniformly coated.
  • the formulation of Comparative Example 1 was observed to be partially coagulated or sticky, and thus the yield of Comparative Example 1 was very low, about 88%, as shown in Table 9 below.
  • Examples 1 to 4 exhibited remarkably high yields compared to Comparative Example 1. The lower the viscosity of hypromellose, the higher the yield.
  • Test Example 4 Evaluation of effect depending on kind of binder contained in the outer layer
  • the dissolution rate of lobeglitazone of the formulations of Examples 1, 5, 6 and 7 in the dissolution medium at pH 1.2 was measured.
  • the dissolution test method was as follows.
  • test solution in the above method was measured as follows.
  • UV spectrophotometer (measurement wavelength: 250 nm)
  • Example 1 The dissolution rates of Examples 1, 5, 6 and 7 in the dissolution medium at pH 1.2 are shown in Table 10 below and FIG. 1.
  • Example 1 using only hypromellose as the binder, 5-min dissolution seldom occurred.
  • Example 5 and 6 where the amount of hypromellose was decreased and lactose hydrate or povidone was used, the early dissolution rate was improved.
  • Example 7 containing all of hypromellose, lactose hydrate and povidone, the early dissolution rate was greatly increased.
  • Test Example 5 Pharmacokinetic testing of combination composition of present invention and single formulations of Comparative Examples 7 and 8
  • PK testing pharmacokinetic testing
  • healthy male volunteers were orally administered with the combination composition or were orally co-administered with single formulations of Comparative Examples 7 and 8.
  • blood sampling was carried out, and respective blood concentrations of lobeglitazone and metformin were measured using LC-MS/MS.
  • the AUC and Cmax values of lobeglitazone and metformin in the combination composition and the orally co-administered formulations of Comparative Examples 7 and 8 were converted into log values to determine a geometric mean, and a 90 % confidence interval relative to the ratio of the geometric mean was calculated.
  • the 90 % confidence interval is in the range of 0.8 to 1.25, two formulations are regarded as having bioequivalence.
  • Control drug 1 Glucophage XR tablet 1000 mg (Comparative Example 7)
  • Control drug 2 Duvie tablet 0.5 mg (Comparative Example 8)
  • Test Example 6 Evaluation of effect depending on kind of plasticizer contained in the outer layer
  • Example 1 and Comparative Examples 2 and 3 were hermetically stored in an HDPE bottle for 8 weeks under accelerated conditions (40 °C, 75 % RH) and in an HDPE bottle for 2 weeks under stress conditions (60 °C), after which the degradation products of lobeglitazone were measured.
  • the measurement method was as follows.
  • UV spectrophotometer (measurement wavelength: 250 nm)
  • the concentration gradient was as follows.
  • Example 1 As shown in Table 15 below, the amount of the related material in Example 1 was not greatly increased up to 8 weeks under accelerated conditions, and satisfactory results appeared. In contrast, as shown in Tables 14 and 15 for Comparative Examples 2 and 3, the individual unknown related material was high from the initial case and the extent of increase thereof was very significant up to 8 weeks under accelerated conditions, and unsatisfactory results appeared from 4 weeks under accelerated conditions. Based on the results of storage under stress conditions for 1 week as shown in Table 16 below, Example 1 exhibited a very low related material value compared to Comparative Examples 2 and 3. Hence, the use of triethyl citrate as the plasticizer is confirmed to be preferable in order to attain the drug stability of the outer layer.
  • Test Example 7 Evaluation of effect depending on amount of plasticizer contained in the outer layer
  • Example 1 (10.00 wt%), Example 8 (5.00 wt%), Example 9 (7.501 wt%), Comparative Example 4 (2.50 wt%), Comparative Example 5 (12.50 wt%), and Comparative Example 6 (15.00 wt%) were obtained by adjusting the amount of triethyl citrate as the plasticizer contained in the coating solution of the outer layer.
  • the coating yield, appearance, hardness and stability were measured. The appearance was observed using a digital microscope (KH-7700, HIROX, Japan), and the hardness of 10 tablets in each of the Examples and Comparative Examples was determined using a hardness meter (PTP-411, Pharma-Test, Germany).
  • the stability was tested in a manner in which the corresponding formulation was hermetically stored in an HDPE bottle for 8 weeks under accelerated conditions (40 °C, 75 % RH) and in an HDPE bottle for 2 weeks under stress conditions (60 °C) and then the degradation products of lobeglitazone were measured.
  • the measurement method was performed in the same manner as Test Example 4.
  • triethyl citrate is contained in an amount of 5 to 10 wt% based on the total weight of the outer layer.
PCT/KR2016/009393 2015-10-28 2016-08-24 Pharmaceutical composition comprising metformin and lobeglitazone WO2017073897A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PH12018500817A PH12018500817A1 (en) 2015-10-28 2018-04-16 Pharmaceutical composition comprising metformin and lobeglitazone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150150108A KR101750690B1 (ko) 2015-10-28 2015-10-28 메트포르민 및 로베글리타존을 포함하는 약제학적 조성물
KR10-2015-0150108 2015-10-28

Publications (1)

Publication Number Publication Date
WO2017073897A1 true WO2017073897A1 (en) 2017-05-04

Family

ID=58630531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/009393 WO2017073897A1 (en) 2015-10-28 2016-08-24 Pharmaceutical composition comprising metformin and lobeglitazone

Country Status (3)

Country Link
KR (1) KR101750690B1 (ko)
PH (1) PH12018500817A1 (ko)
WO (1) WO2017073897A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024063568A1 (en) * 2022-09-23 2024-03-28 Chong Kun Dang Pharmaceutical Corp. Composition and combination therapy for treatment of type 2 diabetes mellitus

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102369679B1 (ko) * 2017-09-29 2022-03-04 한미약품 주식회사 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제
KR102070104B1 (ko) * 2018-06-05 2020-01-29 주식회사 종근당 메트포르민 및 로베글리타존을 포함하는 서방성 약제학적 제제

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040079898A (ko) * 2001-11-29 2004-09-16 메나리니 인터내셔날 오퍼레이션즈 룩셈부르크 에스.아. 메트포르민 및 글리벤클라미드를 포함하는 제 2형 당뇨병치료용 약제학적 조성물
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
KR20130039344A (ko) * 2002-09-20 2013-04-19 안드렉스 랩스 엘엘씨 약제학적 정제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040079898A (ko) * 2001-11-29 2004-09-16 메나리니 인터내셔날 오퍼레이션즈 룩셈부르크 에스.아. 메트포르민 및 글리벤클라미드를 포함하는 제 2형 당뇨병치료용 약제학적 조성물
KR20130039344A (ko) * 2002-09-20 2013-04-19 안드렉스 랩스 엘엘씨 약제학적 정제
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JIN, S.-M. ET AL.: "Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.", DIABETES, OBESITY AND METABOLISM, vol. 17, no. 6, June 2015 (2015-06-01), pages 599 - 602 *
SHIN, D. ET AL.: "Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.", CURRENT MEDICAL RESEARCH AND OPINION, vol. 28, no. 7, 2012, pages 1213 - 1220 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024063568A1 (en) * 2022-09-23 2024-03-28 Chong Kun Dang Pharmaceutical Corp. Composition and combination therapy for treatment of type 2 diabetes mellitus

Also Published As

Publication number Publication date
KR101750690B1 (ko) 2017-06-27
PH12018500817A1 (en) 2018-10-29
KR20170049129A (ko) 2017-05-10

Similar Documents

Publication Publication Date Title
WO2015102400A1 (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin
WO2020040438A1 (ko) 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
WO2017073897A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
WO2016105084A2 (ko) 당뇨병 치료용 약제학적 조성물
WO2018097629A1 (ko) 바레니클린 서방성 제제 및 이의 제조 방법
WO2017146286A1 (ko) 친수성서방폴리머의 매트릭스를 이용한 은행잎 추출물의 약학조성물 및 이를 이용한 경구용 서방성 제제
WO2020009352A1 (ko) 무정형의 다파글리플로진 l-프롤린을 포함하는 약학적 제제 및 이의 제조방법
WO2020242132A1 (ko) 디메틸푸마르산염을 함유한 장용성 정제
WO2018080104A1 (ko) 에스오메프라졸 함유 복합 캡슐제 및 그 제조방법
WO2020130502A1 (ko) 엠파글리플로진 및 시타글립틴을 포함하는 약학적 조성물
WO2019221488A1 (en) Pharmaceutical formulation comprising apixaban and method for preparing the same
WO2018062964A1 (ko) 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법
WO2021167364A1 (en) Pharmaceutical composition comprising esomeprazole and sodium bicarbonate having excellent release properties
WO2015012633A1 (ko) 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
WO2016195153A1 (ko) 약제학적 복합제제
WO2017155350A1 (ko) (±)-2-[2-(3-카르복시프로피오닐옥시)-3-디메틸아미노프로폭시]-3'-메톡시비벤질 또는 그의 염을 포함하는 경구용 약학 조성물
WO2018160011A1 (ko) 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법
WO2021107370A1 (ko) 프로톤펌프억제제와 모사프리드를 함유하는 유핵정 제제
WO2016209061A1 (ko) 모사프리드와 라베프라졸의 복합제제
WO2021125824A1 (ko) 시벤졸린 또는 이의 염을 포함하는 약학 제형
WO2013169082A1 (ko) 보센탄 제어방출성 경구제제
WO2018044020A1 (ko) 에페리손 서방성 미립구의 제조방법 및 에페리손 서방성 미립구와 아세클로페낙 복합제제
WO2013187700A1 (ko) 메트포르민 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 복합제제
WO2017135540A1 (ko) 테넬리글립틴 및 설포닐우레아계 약물을 포함하는 정제
WO2020141825A1 (ko) 정제 및 이의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16860081

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 11201801633V

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 12018500817

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16860081

Country of ref document: EP

Kind code of ref document: A1